findmyKOL

Jennifer Temel, MD

Enriched profile

Professor of Medicine, Harvard Medical School; Clinical Director of Thoracic Oncology, Massachusetts General Hospital · Massachusetts General Hospital

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyMedical OncologyFocusPalliative Care and End-of-Life Issues+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2025–2025NIH funding2004–2026

Jennifer Temel is Professor of Medicine, Harvard Medical School; Clinical Director of Thoracic Oncology, Massachusetts General Hospital at Massachusetts General Hospital. OpenAlex indexes 645 publications with 36,476 citations (h-index 84); ClinicalTrials.gov lists 16 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.

Data verified 16 Oct 2026

Overview

Updated 16 Oct 2026

Jennifer Temel, MD, is Professor of Medicine, Harvard Medical School at Massachusetts General Hospital. The public record shows 645 publications with 36,476 citations (h-index 84), centered on Palliative Care and End-of-Life Issues, Cancer survivorship and care, Palliative and Oncologic Care. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 1 companies, 10 NIH-funded awards (2004–2026).

  • Most recent indexed publication: 2026 · Neuro-oncology
  • Top research focus: Palliative Care and End-of-Life Issues
  • 16 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 1 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)8 trialsSmall Cell Lung Carcinoma3 trialsPancreatic Cancer3 trialsGastroesophageal Cancer3 trialsHepatobiliary Cancer3 trialsStomach Neoplasms3 trialsEsophageal Neoplasms3 trialsLiver Neoplasms3 trialsMesothelioma2 trialsBreast Cancer2 trialsExanthema1 trialOvarian / Gynecologic Cancer1 trialMelanoma1 trialHead & Neck Cancer1 trialSarcoma1 trialUterine Cervical Neoplasms1 trialUterine Neoplasms1 trialComa1 trialDepression (MDD)1 trialMesothelioma, Malignant1 trialBile Duct Neoplasms1 trialDyspnea1 trialLeukemia (AML/ALL/CML/CLL)1 trialLeukemia, Myeloid, Acute1 trialRecurrence1 trial

Research focus

OpenAlex concept fingerprint
Palliative Care and End-of-Life IssuesCancer survivorship and carePalliative and Oncologic CareLung Cancer Diagnosis and TreatmentPatient-Provider Communication in Healthcare

Drugs & molecules

across trials, industry payments and publications
Enhertugeneric · TrastuzumabClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Massachusetts General HospitalClinical trials13Industry payments—Alliance for Clinical Trials in OncologyClinical trials1Industry payments—AstraZeneca Pharmaceuticals LPClinical trials—Industry payments1Helsinn Therapeutics (U.S.), IncClinical trials1Industry payments—Spectrum Pharmaceuticals, IncClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
645publications

Distinct works indexed by OpenAlex, matched via ORCID; 35 in PubMed.

36,476citations

Total citations across indexed works.

84h-index

Hirsch index (OpenAlex). i10-index 253.

Clinical & industry

trials, payments and federal funding
16clinical trials

Investigator role on registered studies.

View trials ↓
1companies · 2025–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
10NIH grants · 2004–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:

All 16 trial records: search, sort and filter.Explore →

Industry payments

Updated 16 Oct 2026

1 company reported payments to CMS in program years 2025–2025. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Kinase inhibitor100%
    Tagrisso100%
    Part D<11 patients
Where care is delivered (Part B)65.4% facility · 34.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 16 Oct 2026

10 NIH research awards on record, funded 2004–2026 per NIH RePORTER. The latest:

All 39 award records: search, sort and filter.Explore →

Congress activity

Updated 16 Oct 2026

202 congress contributions (2004–2026) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:

All 202 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 35 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
    Article7,570 citations2010
    doi.org ↗
  2. 02
    Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
    Article3,609 citations2011
    doi.org ↗
  3. 03
    Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
    Article2,160 citations2017
    doi.org ↗
  4. 04
    Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial
    Article859 citations2017
    doi.org ↗
  5. 05
    Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non–Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care
    Article704 citations2011
    doi.org ↗
All 645 cited works: search, sort and filter.Explore →

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Areej R El-Jawahri296Joseph Andrew Greer254Vicki Ann Jackson181William F. Pirl158Lara N. Traeger156Joseph A. Greer115Ryan David Nipp109Elyse Richelle Park75Emily R. Gallagher73Jamie M. Jacobs65Nora Horick55Inga Tolin Lennes47Lecia Van Dam Sequist47Thomas William LeBlanc46Thomas James Lynch43Daniel E. Lage41Laura A. Petrillo39David P. Ryan37Deborah Anne Forst36Harry B. Vandusen36Alona Muzikansky35Rebecca Suk Heist35Juliet C. Jacobsen35Richard Andrew Newcomb34Thomas R. Spitzer28Alice Tsang Shaw28Justin R. Eusebio27Barbara J. Cashavelly26Angelo E. Volandes25Dustin John Rabideau25Yi‐Bin Chen24Joel Nathan Fishbein24Mihir M. Kamdar23Kathryn Elizabeth Post23Charn‐Xin Fuh22Lauren P. Waldman22Zachariah Michael DeFilipp22Simone P. Rinaldi22Amir Tahmasb Fathi21Justin F. Gainor21

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/jennifer-temel-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Harvard Medical School (Professor of Medicine)
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗
  • Co-Director

    Cancer Outcomes Research and Education Program, Massachusetts General Hospital Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗
  • Co-leader

    Dana-Farber/Harvard Cancer Center Outcomes Research Program

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.